Recent news highlights Centene's Q3 2026 financial results, operational updates, and regulatory impacts on membership and costs.

• Centene reported Q3 2026 results with managed care membership of 25.7 million, down 8% year-over-year, and total revenues of $50.6 billion, a 2% increase year-over-year [N1].
• Premium and service revenues grew 0.5% year-over-year to $45.1 billion in Q3 2026 [N1].
• Health Benefits Ratio remained steady at 92.7% in Q3 2026 compared to the prior year, while SG&A expense ratio increased slightly to 7.2% [N1].
• GAAP diluted loss per share was $(0.14) for Q3 2026, with adjusted diluted EPS of $0.58 [N1].
• Centene narrowed its Medicare Advantage footprint amid elevated costs, reflecting strategic adjustments in that segment [N8].
• Regulatory changes including New York's termination of Essential Plan-5 and the One Big Beautiful Bill Act are influencing Medicaid membership and program design [N1][N8].
• The company continues to expand Medicaid managed care contracts in states such as Nevada, California, Iowa, and Mississippi [N1].
• Centene is focused on clinical initiatives, fraud prevention, and network design to address ongoing medical cost pressures [N1].

Centene’s leadership in Medicaid and Medicare markets, combined with its integrated care approach for complex populations, supports operational scale and potential cost efficiencies. The company’s focus on clinical initiatives, fraud prevention, and network design aims to mitigate rising medical costs. Expansion of Medicaid managed care contracts and continued innovation in care management could enhance member outcomes and operational performance. Strong liquidity and adjusted profitability metrics provide financial flexibility to navigate regulatory changes and invest in growth opportunities [S1][S2][N1].

Centene faces risks from regulatory and policy changes that may reduce Medicaid and Marketplace membership, such as eligibility redeterminations and subsidy expirations. Elevated medical cost trends driven by increased demand, new high-cost pharmaceuticals, and provider billing practices pressure margins. The company’s GAAP losses and significant operating cash outflows reflect ongoing challenges in cost management. Uncertainty around implementation of new regulations and potential reductions in federal funding could impact revenues and profitability. Competitive pressures in Medicare Advantage and Marketplace segments may also constrain growth [S1][S2][N8].

Centene’s moat is anchored in its scale as the largest Medicaid and Marketplace insurer and the largest stand-alone Medicare PDP provider in the U.S., serving over 25 million members. Its extensive state-based Medicaid contracts and integrated care models, especially for dual-eligible populations, create high barriers to entry. The company’s local approach with community-focused teams and partnerships with providers and policymakers enhances member engagement and care coordination. Regulatory expertise and long-standing relationships with government agencies further strengthen its competitive position. Additionally, Centene’s diversified portfolio across Medicaid, Medicare, and Commercial segments provides resilience against market and policy shifts [S1][S2].

• Regulatory and Policy Changes: Changes such as the One Big Beautiful Bill Act and Marketplace subsidy expirations may reduce membership and alter program funding, impacting revenues and cost structures.
• Medical Cost Inflation: Rising medical demand, expanded access, and high-cost pharmaceuticals increase medical expenses, challenging margin management.
• Membership Declines: Post-pandemic Medicaid eligibility redeterminations and Marketplace market contraction have led to membership decreases, affecting premium revenues.
• Operational Execution: Managing elevated costs, regulatory compliance, and integration of care models requires effective execution to maintain profitability and service quality.
• Cash Flow and Profitability: Operating cash outflows and GAAP losses highlight financial pressures that could affect investment capacity and shareholder returns.

• Centene Corp is the nation's largest managed care company focused on underserved populations, serving more than 1 in 15 individuals across the U.S. including Medicaid, Medicare (including Medicare Prescription Drug Plans), and Health Insurance Marketplace members [S1].
• Centene operates four segments: Medicaid, Medicare, Commercial, and Other (including specialty pharmacy, vision, dental, behavioral health, and centralized services) [S1].
• For 2025, Medicaid accounted for 57% of revenues, Commercial 21%, Medicare 19%, and Other 3% [S1].
• Centene had 27.6 million members as of December 31, 2025 [S1].
• Medicaid segment includes TANF, Medicaid Expansion, ABD, CHIP, LTSS, Foster Care, Medicare-Medicaid Plans (ended 12/31/2025), and other state-based programs [S1].
• Medicare segment includes Medicare Advantage, Dual Eligible Special Needs Plans (D-SNPs), Medicare Prescription Drug Plans (PDP), and Medicare Supplement [S1].
• Commercial segment includes ACA Marketplace products and individual and group commercial plans [S1].
• Centene is the largest Medicaid and Marketplace insurer and the largest stand-alone PDP provider in the U.S. [S1].
• Medicaid membership was 12.5 million in 30 states as of December 31, 2025 [S1].
• Medicare Advantage membership was 1.0 million across 32 states as of December 31, 2025 [S1].
• Medicare PDP membership was 8.1 million as of December 31, 2025 [S1].
• Centene's business is affected by regulatory changes including the One Big Beautiful Bill Act (OBBBA) impacting Medicaid eligibility and funding starting 2026-2027, and changes to Marketplace subsidies and eligibility [S1,S2].
• The company is focused on integrated care models for dual-eligible members through D-SNPs, with regulatory requirements for integrated care starting 2027 and 2030 [S1,S2].
• Centene reported Q3 2026 results with managed care membership of 25.7 million, a decrease of 2.3 million year-over-year [S2,N1].
• Q3 2026 total revenues were $50.6 billion, a 2% increase year-over-year [S2,N1].
• Premium and service revenues were $45.1 billion, up 0.5% year-over-year [S2,N1].
• Health Benefits Ratio (HBR) was 92.7% in Q3 2026, unchanged from Q3 2025 [S2].
• SG&A expense ratio was 7.2% in Q3 2026, slightly higher than 7.0% in Q3 2025; adjusted SG&A ratio was 6.5% [S2].
• Operating cash flows used $3.7 billion in Q3 2026 due to timing of pass-through payments [S2].
• GAAP diluted loss per share was $(0.14) in Q3 2026; adjusted diluted EPS was $0.58 [S2].
• As of September 30, 2026, Centene had $20.7 billion in cash and equivalents and $2.9 billion in short-term investments [S2].
• Current assets were $45.5 billion and current liabilities $39.1 billion as of September 30, 2026, yielding a current ratio of 1.16 and cash ratio of 0.6 [S2].
• Centene continues to face elevated medical cost trends driven by increased demand, expanded access, and high-cost pharmaceuticals [S2].
• The company is working with states to set Medicaid premium rates aligned with population acuity and medical cost trends [S2].
• Marketplace membership declined in early 2026 due to regulatory changes including expiration of enhanced subsidies and new eligibility rules [S2].
• Centene is focused on clinical initiatives, care management, network design, and fraud prevention to address cost trends [S2].
• Recent contracts include Medicaid managed care expansions in Nevada, California dental services, Iowa Health Link, and Mississippi Coordinated Care Organization [S2].
• New York terminated its Essential Plan-5 in July 2026, affecting Medicaid expansion coverage [S2].
• Centene's Medicare Advantage footprint is narrowing amid elevated costs [N8].